[1]孙 茜.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效[J].医学信息,2022,35(20):60-62.[doi:10.3969/j.issn.1006-1959.2022.20.014]
 SUN Qian.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(20):60-62.[doi:10.3969/j.issn.1006-1959.2022.20.014]
点击复制

布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年20期
页码:
60-62
栏目:
论著
出版日期:
2022-10-15

文章信息/Info

Title:
Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959(2022)20-0060-03
作者:
孙 茜
(佳木斯市中心医院呼吸科,黑龙江 佳木斯 154002)
Author(s):
SUN Qian
(Department of Respiratory,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
慢性阻塞性肺疾病布地奈德福莫特罗噻托溴铵肺功能
Keywords:
Chronic obstructive pulmonary diseaseBudesonide formoterolTiotropium bromideLung function
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2022.20.014
文献标志码:
A
摘要:
目的 研究布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效。方法 选取2020年1月-2021年10月佳木斯市中心医院收治的40例慢性阻塞性肺疾病患者,采用随机数字表法分为对照组与观察组,各20例。对照组给予布地奈德福莫特罗吸入治疗,观察组给予布地奈德福莫特罗联合噻托溴铵吸入剂治疗,比较两组临床疗效、肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、第1秒用力呼气量占肺活量百分比(FEV1%)]、血气指标[血氧饱和度(SaO2)、动脉血二氧化碳分压(PaCO2)、pH值]、炎性指标[C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]。结果 观察组治疗总有效率为100.00%,高于对照组的85.00%(P<0.05)。观察组治疗后FVC、FEV1、FEV1%、SaO2、pH高于对照组,PaCO2、CRP、IL-6、TNF-α低于对照组(P<0.05)。结论 布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效确切,可有效改善患者的肺功能及血气指标,抑制炎性反应,有利于病情转归。
Abstract:
Objective To study the efficacy of budesonide formoterol combined with tiotropium bromide inhalation in the treatment of chronic obstructive pulmonary disease.Methods Forty patients with chronic obstructive pulmonary disease admitted to Jiamusi Central Hospital from January 2020 to October 2021 were selected and divided into a control group and an observation group according to the random number table method, with 20 cases in each group. The control group was treated with budesonide formoterol inhalation, and the observation group was treated with budesonide formoterol combined with tiotropium bromide inhalation. The clinical efficacy, pulmonary function indexes [forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), forced expiratory volume in the first second as a percentage of vital capacity (FEV1%)], blood gas indexes [blood oxygen saturation (SaO2), arterial partial pressure of carbon dioxide (PaCO2), pH value], inflammatory indexes [C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)] were compared between the two groups.Results The total effective rate of treatment in the observation group was 100.00%, which was higher than 85.00% in the control group (P<0.05). After treatment, FVC, FEV1, FEV1%, SaO2 and pH in the observation group were higher than those in the control group, while PaCO2, CRP, IL-6 and TNF-α were lower than those in the control group (P<0.05).Conclusion Budesonide formoterol combined with tiotropium bromide inhalation is effective in the treatment of chronic obstructive pulmonary disease, which can effectively improve the lung function and blood gas index of patients, inhibit the inflammatory response, and is conducive to the prognosis of the disease.

参考文献/References:

[1]Ritchie AI,Wedzicha JA.Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations[J].Clin Chest Med,2020,41(3):421-438.[2]Segal LN,Martinez FJ.Chronic obstructive pulmonary disease subpopulations and phenotyping[J].J Allergy Clin Immunol,2018,141(6):1961-1971.[3]李亚宁.布地奈德福莫特罗粉吸入剂对慢性阻塞性肺疾病稳定期患者肺功能改善的作用[J].中国药物与临床,2020,20(16):2760-2762.[4]Lin YH,Liao XN,Fan LL,et al.Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D[J].PLoS One,2017,12(8):183-187.[5]Ji J,von Schéele I,Billing B,et al.Effects of budesonide on toll-like receptor expression in alveolar macrophages from smokers with and without COPD[J].Int J Chron Obstruct Pulmon Dis,2016,11:1035-1043.[6]张凡.噻托溴铵粉联合布地奈德福莫特罗粉维持治疗COPD的临床效果观察[J].中国临床研究,2015,28(8):1030-1032.[7]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.[8]王娜,许恩喜,陈昕晟,等.噻托溴铵、布地奈德/福莫特罗与异丙托溴铵治疗慢性阻塞性肺疾病的临床疗效和药物经济学评价[J].湖北科技学院学报(医学版),2020,34(5):405-408.[9]刘斌,冉献贵,邢青峰,等.噻托溴铵联合信必可都保治疗对慢阻肺患者肺功能和运动耐量及不良反应的影响[J].河北医学,2019,25(7):1108-1112.[10]张琼.布地奈德福莫特罗吸入治疗成人哮喘合并慢性阻塞性肺疾病临床效果观察[J].山西医药杂志,2021,50(17):2556-2558.[11]刘颖,薄晓霞,张亚娟.布地奈德福莫特罗、噻托溴铵、家庭无创正压通气对慢性阻塞性肺疾病患者影响的研究[J].临床肺科杂志,2018,23(8):1394-1397.[12]张贵平.布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的效果及对生活质量的影响分析[J].中外医学研究,2017,15(31):59-61.[13]姚淑芳,林建锋,李侨华.哮喘-慢性阻塞性肺疾病重叠综合征使用布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗的效果观察[J].实用医技杂志,2018,25(9):1015-1016.[14]赵瑞芬,李霞,杨亚萍,等.噻托溴铵联合布地奈德/福莫特罗对慢性阻塞性肺疾病患者血管内皮功能及T淋巴细胞亚群的影响[J].心肺血管病杂志,2018,37(2):98-102.[15]瞿美君,曹奇峰.布地奈德/福莫特罗联合噻托溴铵治疗稳定期慢性阻塞性肺疾病疗效观察[J].药物流行病学杂志,2015,24(7):394-396,399.[16]许柳柳,朱洁晨,卞宏,等.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺疗效及对CRP、SaO2、pH水平影响[J].现代生物医学进展,2020,20(22):4369-4372.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
 ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(20):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
 CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(20):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
 WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(20):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
 LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(20):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
 LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(20):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
 ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(20):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
 JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(20):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
 ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(20):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
 ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(20):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]

更新日期/Last Update: 1900-01-01